Cytokinetics

Yahoo Finance • 4 months ago

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

On July 23, 2024, Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,300 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider n... Full story

Yahoo Finance • 6 months ago

Insider Sale: VP, Chief Accounting Officer Robert Wong Sells Shares of Cytokinetics Inc (CYTK)

On June 3, 2024, Robert Wong, Vice President, Chief Accounting Officer of Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 13,011 shares of the company. The transaction was documented in a recent SEC Filing. Following this transaction, t... Full story

Yahoo Finance • 7 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares o... Full story

Yahoo Finance • 8 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 9 months ago

Cytokinetics Inc (CYTK) Reports Q4 and Full Year 2023 Financial Results

Net Loss: Q4 net loss of $136.9 million ($1.38 per share), full-year net loss of $526.2 million ($5.45 per share). Revenue: Q4 revenue of $1.7 million, full-year revenue of $7.5 million, reflecting a significant decrease from the previous... Full story

Yahoo Finance • 9 months ago

16 Best Russell 2000 Stocks To Buy According To Hedge Funds

In this article, we discuss 16 best Russell 2000 stocks to buy. If you want to skip our discussion on the Russell 2000 index and overall stock market performance, head over to 5 Best Russell 2000 Stocks To Buy According To Hedge Funds. In... Full story

Yahoo Finance • 9 months ago

Cytokinetics, Incorporated (CYTK) Rose on Successful Clinical Trial

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Small-cap stocks had excellent increases in the... Full story

Yahoo Finance • 10 months ago

Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition

Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the promising heart-drug developer. The biotech company, currently running a sale pr... Full story

Yahoo Finance • 10 months ago

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal

Novartis is closing in on a takeover of Cytokinetics, the Wall Street Journal reported Monday, leading CYTK stock to soar in afternoon action. Continue reading... Full story

Yahoo Finance • 11 months ago

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Bu... Full story

Yahoo Finance • 12 months ago

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International Symposium on ALS/MND taking place in Basel, Switzerland and online from... Full story

Yahoo Finance • last year

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • last year

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2023 it granted stock options to purchase an aggregate of 22,350 shares of common stock to five... Full story

Yahoo Finance • last year

Cytokinetics Reports Third Quarter 2023 Financial Results

On Track for Topline Results from SEQUOIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements... Full story

Yahoo Finance • last year

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in November: UBS BioPharma Confe... Full story

Yahoo Finance • last year

Cytokinetics to Announce Third Quarter Results on November 2, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at 4:00 PM Eastern Time. Following the anno... Full story

Yahoo Finance • last year

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Commercial Readiness Activities Leverage... Full story

Yahoo Finance • last year

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the baseline characteristics of patients randomized in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understa... Full story

Yahoo Finance • last year

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The... Full story

Yahoo Finance • last year

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on Octobe... Full story